PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) announced that a prospective analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial showed that total hospital stay costs were lowest with Angiomax monotherapy (mean difference range: $184 to $1,081, p <0.001 for overall comparison) and at 30 days (mean difference range: $123 to $938, p < 0.005). Angiomax monotherapy was associated with an initial hospital cost savings of $572 per patient and a total 30 day cost savings of $422 per patient when compared to heparin and GPI administered prior to catheterization, in patients with moderate and high- risk (UA/NSTEMI) acute coronary syndrome (ACS).
